# Tempero Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tempero-bio

- Industry: Biotechnology
- Headquarters: Oakland, US
- Website: www.temperobio.com/
- Total disclosed funding: $70M
- Latest round: Series B (Mar 24, 2025)
- Investors on record: 3

## About

Tempero Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for substance use disorders and related conditions through cutting-edge research and development efforts.Tempero Bio focuses on the advancement of treatments for substance use disorders. Founded in 2020 and headquartered in Oakland, US, the company has successfully completed 1 deal. The most recent funding round was a Series B in March 2025, raising USD 70.000 mn led by 8VC, with participation from Aditum Bio and Khosla Ventures. The founder's background is not specified in available information.Tempero Bio is a clinical-stage biopharmaceutical company focused on developing innovative treatments for substance use disorders (SUDs) and related conditions. Their primary product offering, TMP-301, is an orally-available metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator. This therapeutic candidate is being investigated for its efficacy in treating various SUDs, including Cocaine Use Disorder (CUD) and Alcohol Use Disorder (AUD), with ongoing research into its potential for addressing Opioid Use Disorder (OUD) and Polysubstance Use Disorder (PUD). TMP-301 operates by modulating glutamate signaling in the brain, which is crucial for normal brain function and is often disrupted in individuals suffering from addiction. Tempero Bio's products are primarily aimed at the U.S. market, addressing a significant need for effective treatment options as over 40 million individuals in the country are affected by substance use disorders.While specific revenue figures for Tempero Bio are not disclosed, the company's revenue model centers on partnerships and collaborations primarily within the pharmaceutical and healthcare sectors. The firm focuses on advancing TMP-301 through clinical trials, and revenue may be generated through potential licensing agreements or joint ventures with larger pharmaceutical companies interested in commercializing their therapies. Transactions typically involve milestones associated with drug development phases, which could include payments upon successful completion of clinical trials or regulatory approvals. By positioning TMP-301 as a groundbreaking therapeutic option, Tempero Bio aims to attract interest from investors and partners looking to contribute to addressing the urgent demand for effective addiction treatments.Tempero Bio plans to utilize the recent Series B funding of USD 70.000 mn to advance TMP-301 through Phase 2 trials for alcohol and cocaine use disorders and support Phase 3 and preclinical studies for other indications. The company is focused on launching new products to further address the needs of individuals suffering from substance use disorders. Specific geographical expansion plans have not been detailed, but the emphasis remains on enhancing the clinical development of their therapies to reach critical milestones.

## Funding rounds

- Series B, Mar 24, 2025, $70M — Khosla Ventures, 8VC, Aditum Bio

## Investors

- Khosla Ventures (https://capitalatlas.ai/funds/khosla-ventures) — Series B
- 8VC (https://capitalatlas.ai/funds/8vc) — Series B
- Aditum Bio (https://capitalatlas.ai/funds/aditum-bio) — Series B